logo
Is it perimenopause ... or something else? A new wearable is helping women demystify symptoms like hot flashes and brain fog.

Is it perimenopause ... or something else? A new wearable is helping women demystify symptoms like hot flashes and brain fog.

Yahooa day ago
Many women say they don't feel informed at all about this stage of life.
Why is it suddenly harder to find the right word or remember the name of the restaurant you used to go to? When did sleeping through the night become such a rarity? And what's up with that shoulder pain that came out of nowhere? Welcome to perimenopause — the transition period that kicks off years before you officially reach menopause. While hot flashes and night sweats steal most of the spotlight, there are many subtler and seemingly random symptoms that can crop up (itchy ears, anyone?). It can leave women feeling blindsided and lost, like they're navigating an ever-shifting landscape without a compass or a map.
A 2022 survey of nearly 950 perimenopausal women in the U.K. found that more than 60% said they didn't feel informed at all about this stage of life. Other than hot flashes, 'most of the women were entirely unaware of the wide array of symptoms and so did not connect them to the perimenopause,' according to the study authors.
A more recent survey of nearly 4,500 American women revealed that more than 55% of those ages 30 to 35 had symptoms that could be classified as 'moderate' or 'severe' on the Menopause Rating Scale (MRS), a common questionnaire that measures the intensity of menopause symptoms. That increased to more than 64% in women ages 36 to 40. But the researchers behind the survey found that most women don't talk to a health care professional about their symptoms until they reach their mid-50s. Many just muscle through an uncomfortable array of symptoms.
A lot of it comes down to the fact that almost no one is taught about perimenopause and menopause (and most doctors aren't adequately trained in it), so they may not know what signs to look out for and how to best manage symptoms. Technology is stepping in to fill the gap. The latest: a wearable device that's specifically designed to help women track perimenopause symptoms and figure things out sooner. It's called Peri by identifyHer, and it's a first-of-its-kind tool to help midlife women be better informed about this stage of life and their health. Here's what's behind this innovative technology, plus what menopause experts think.
The problem: Figuring out whether you're in perimenopause is like playing a guessing game — but with your health. And managing symptoms can be difficult if you don't know where to start.
By the numbers: A 2021 survey found that 44% of women were unaware of perimenopause until they started experiencing symptoms, while 46% were not expecting perimenopause when it started. A more recent survey by Ohio State Wexner Medical Center revealed that more than 60% of women believe they will reach menopause in their 40s. However, perimenopausal symptoms can start as early as your 30s, while the average age of menopause is 51, which can catch some women off guard.
The solution: Peri by identifyHer is a wearable device with a corresponding app that's designed for women in perimenopause. It was a 2025 CES Innovation Awards Honoree and is relatively simple to use.
The tool has an adhesive that sticks to your torso and collects data on everything from hot flashes and night sweats to sleep, anxiety and brain fog, sending that information to the app. It also gives personalized feedback on how to manage your specific symptoms.
Chief executive officer and cofounder Heidi Davis tells Yahoo that the device was designed with the goal of supporting women. 'There's a critical lack of support and objective data when it comes to perimenopause — a stage that affects nearly every woman yet is still poorly understood,' she says. 'Beyond helping women in the moment, Peri aims to help close the gender data gap by gathering women-specific health data. Perimenopausal symptoms can be an early signal for future health outcomes, and understanding them better is key to keeping women healthier and more productive for longer.'
Peri continuously monitors perimenopausal symptoms over time to analyze patterns and provide advice on next steps for women. 'These include tailored feedback on lifestyle around diet and exercise, feedback on hormone replacement therapy if applicable and tracking of symptoms across the cycle — helping women identify underlying causes of things like sleep disruption, e.g., is it night sweats? Anxiety?' Davis says. 'It also helps prompt more informed conversations with health care providers by offering a clear picture of what's going on.' Meaning, you can take the app's findings to your doctor to go over what you're experiencing in detail.
Doctors who treat women in perimenopause and menopause say these details can be helpful. 'Digitalized health is one of the best ways to implement health care and to truly understand a patient's progression, recovery and journey through certain medical conditions,' women's health expert Dr. Jessica Shepherd, an ob-gyn in Dallas and author of the book Generation M: Living Well in Perimenopause and Menopause, tells Yahoo. 'The hormonal shifts seen in perimenopause and menopause are able to be tracked with a device such as this, which is valuable, especially since the journey of this transition is very hard to contextualize to a group of women.'
Dr. Lauren Streicher, a clinical professor of obstetrics and gynecology at Northwestern University Feinberg School of Medicine, tells Yahoo that a device like this can help women identify symptoms they may not realize are from perimenopause and share them with their health care provider. 'Women are not aware of all of their hot flashes,' she says, pointing out that these can happen overnight when women are sleeping. 'There is value in knowing how many hot flashes you're actually having and whether whatever you're doing to try to make them go away is working,' Streicher says.
That actually matters more than just knowing your health stats. 'There is a correlation between the severity of symptoms in perimenopause, such as hot flashes and night sweats, that can have a direct link to future health implications, such as heart disease, neurodegenerative diseases and overall quality of life,' Shepherd says. 'There is data that shows the increased severity of either hot flashes or night sweats was associated with a higher risk of cardiovascular disease.'
While some experts say the wearable device is useful, Dr. Mary Jane Minkin, a clinical professor of obstetrics and gynecology and reproductive sciences at Yale School of Medicine and founder of Madame Ovary, says you don't need it to help you navigate perimenopause comfortably. 'As a general rule, things that are helpful for perimenopausal symptoms are also very good for medical health in general: getting lots of exercise (both aerobic and strength training) and eating a healthy diet — some varieties of a Mediterranean diet are good for most women,' Minkin tells Yahoo. 'Stopping smoking and avoiding excess alcohol — I discourage women from drinking more than one drink a day — are also good to minimize perimenopausal symptoms.'
Minkin says it's also crucial to find a health care provider who understands perimenopause. (She recommends focusing on providers who are members of the Menopause Society and Menopause Society-certified practitioners.)
Davis says she hopes her tool can help women make sense of what's happening to their bodies at this stage of life. 'Symptoms [of perimenopause] are often dismissed or misattributed, and women are left to manage on their own,' she says. 'There's a massive opportunity to bring clarity, support and personalization to this experience.'
Preorders for Peri open in September 2025, and the first devices will ship in October.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

Yahoo

time6 minutes ago

  • Yahoo

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in to access your portfolio

4 killed in medical transport plane crash on Navajo Nation, tribal authorities say
4 killed in medical transport plane crash on Navajo Nation, tribal authorities say

CNN

time8 minutes ago

  • CNN

4 killed in medical transport plane crash on Navajo Nation, tribal authorities say

Four people were killed Tuesday when a medical transport plane crashed on Navajo Nation land in Arizona, according to tribal police. 'The small aircraft was enroute to pick up a patient from a nearby hospital, when the crash occurred,' Navajo Nation Police said on Facebook. The accident took place around 12:40 p.m. near Chinle, Arizona, according to police. 'We extend our deepest condolences to their family and loved ones during this time,' Navajo Police said. The plane was a Beechcraft 300, the National Transportation Safety Board said. 'NTSB investigators are en route to the scene (and) expected to start arriving tonight. Once on site, the investigators will begin the process of documenting the scene and examining the aircraft. The aircraft will then be recovered to a secure facility for further evaluation,' Sarah Taylor Sulick, a spokesperson for the NTSB, told CNN. CNN has reached out to the medical transport company for comment.

Biden's doctor thought cognitive tests were 'meaningless,' ex-aide Bruce Reed told investigators
Biden's doctor thought cognitive tests were 'meaningless,' ex-aide Bruce Reed told investigators

Fox News

time17 minutes ago

  • Fox News

Biden's doctor thought cognitive tests were 'meaningless,' ex-aide Bruce Reed told investigators

Former White House physician Kevin O'Connor previously dismissed cognitive tests as "meaningless," ex-Biden administration aide Bruce Reed told House investigators on Tuesday, according to a source familiar with the proceedings. Reed, who served as White House deputy chief of staff for policy, is the ninth member of former President Joe Biden's inner circle to sit down with House Oversight Committee lawyers. A source familiar with his interview told Fox News Digital that Reed attributed Biden's disastrous 2024 debate performance against then-candidate Donald Trump to the former president's stutter, a condition that's been well-documented and Biden himself has publicly acknowledged. But his meandering and seemingly tired demeanor on stage with Trump alarmed both Democrats and media pundits, who saw it as a glaring sign of Biden's advanced age. It precipitated both a public and private push by left-wing lawmakers to get Biden to drop out of the race – which he did in July 2024. When asked whether public concerns about Biden's mental acuity were legitimate, however, the source told Fox News Digital that Reed said he believes Americans should not have had any concerns about the ex-president's mental faculties. Reed also told investigators that "the president's communications team anticipated that the issue of a cognitive test would likely be raised" in Biden's interview with ABC News host George Stephanopoulos following the debate. "Mr. Reed further explained that President Biden's physician, Dr. Kevin O'Connor, dismissed cognitive tests as 'meaningless,'" the source said. O'Connor was among the first former White House officials summoned by House investigators, and sat down with them last month after being compelled via subpoena. But his sit-down lasted less than an hour, with the doctor opting to invoke the Fifth Amendment to avoid answering all questions but his name. His lawyers said at the time that was due to concerns about violating doctor-patient confidentiality. In his own interview Tuesday, Reed also defended the Biden 2024 campaign's preference to hold the debate earlier than typical for a presidential cycle, the source said. "During his interview, Mr. Reed stated that the decision to hold the debate early was a deliberate strategy to get ahead of early voting and the Olympics. He emphasized that the campaign's push for the early debate was unrelated to concerns about President Biden's age," the source said. Excerpts of Reed's opening statement to investigators, obtained by Fox News Digital via a second source familiar with the interview, show he emphatically defended Biden's cognitive abilities. "While I can only speak to my own observations, I had the benefit of working with President Biden nearly every day of his presidency. Despite his age, President Biden maintained an unrelenting work ethic, embraced complex policy issues, and approached decisions with diligence and deliberation," Reed said, according to the source. Reed also described Biden as "a demanding boss who routinely grilled staff members on a topic until he reached the limits of our knowledge so he could judge whether to have confidence in our advice," though "that didn't mean he'd take it." "From the first days in the White House to the last, President Biden governed the same way he'd gotten there, by trusting his own values and instincts," Reed said, according to the source. "There is no tougher test than the presidency: President Biden asked tough questions, made tough decisions, and led his country well in challenging times for the nation and the world." Chairman James Comer, R-Ky., is probing whether Biden's senior aides worked to cover up evidence of mental decline in the former president, and whether that meant Biden was not making the final decision on executive matters signed by autopen. Of particular interest to Comer is the myriad of clemency orders Biden signed in the latter half of his presidency, though the former president told The New York Times last month that he was behind every decision. His allies have also dismissed Comer's probe as purely political. Fox News Digital reached out to Reed's counsel and lawyers for O'Connor for comment but did not hear back by press time.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store